<DOC>
	<DOC>NCT01018953</DOC>
	<brief_summary>The purpose of the protocol is to assess the efficacy and safety of BIM 23A760 on patient's overall satisfaction in terms of symptom relief (diarrhoea and/or flushes) in patients with carcinoid syndrome after 24 weeks of treatment.</brief_summary>
	<brief_title>Study to Assess the Efficacy and Safety of Different Doses of BIM 23A760 in Patients With Carcinoid Syndrome</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Carcinoid Tumor</mesh_term>
	<mesh_term>Malignant Carcinoid Syndrome</mesh_term>
	<mesh_term>Serotonin Syndrome</mesh_term>
	<mesh_term>Dopamine</mesh_term>
	<mesh_term>Somatostatin</mesh_term>
	<criteria>The patient has a carcinoid syndrome defined as ≥3 stools/day and/or ≥3 flushes/week. The patient has elevated 5Hydroxyindoleacetic acid (above upper limit normal). The patient has a welldifferentiated midgut carcinoid tumour or serotonin secreting tumour of unknown localisation with hepatic metastasis. The patient has undergone surgery related to a neuroendocrine tumour (NET) within 4 weeks prior to study entry or has surgery planned during the study. The patient has received short acting somatostatin analogues (SSAs) within 2 weeks before study entry or has received short acting SSAs for more than 3 months. The patient has received a radiolabelled SSA at any time before study entry. The patient has received long acting SSAs under certain circumstances. The patient has previously received any specific anti tumour treatment such as chemotherapy, (chemo)embolisation, radiotherapy or interferon in the last 6 months. The patient has signs or symptoms of cardiac insufficiency. The patient has an ejection fraction &lt;40% and/or clinically severe cardiac valvular regurgitation.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>August 2015</verification_date>
</DOC>